Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222).
Belij-Rammerstorfer S. et al, (2025), EBioMedicine, 118
Pf8: an open dataset of Plasmodium falciparum genome variation in 33,325 worldwide samples
Abdel Hamid MM. et al, (2025), Wellcome Open Research, 10, 325 - 325
Establishing laboratory reference ranges for haematological and biochemical blood parameters in adults and children in Kilifi, Kenya
Downs LO. et al, (2025), Wellcome Open Research, 10, 312 - 312
Establishing laboratory reference ranges for adults and children in Kilifi, Kenya
Downs LO. et al, (2024)
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK. et al, (2024), PLoS Med, 21
Nutritional supplementation in children with severe pneumonia in Uganda and Kenya (COAST-Nutrition): a phase 2 randomised controlled trial.
Kiguli S. et al, (2024), EClinicalMedicine, 72
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo MS. et al, (2024), Lancet, 403, 533 - 544
A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial).
Maitland K. et al, (2024), Wellcome Open Res, 9
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
[A global core outcome measurement set for snakebite clinical trials].
Abouyannis M. et al, (2023), Med Trop Sante Int, 3
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Kimathi D. et al, (2023), Lancet Infect Dis, 23, 974 - 982
Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Odera DO. et al, (2023), Sci Transl Med, 15
A global core outcome measurement set for snakebite clinical trials.
Abouyannis M. et al, (2023), Lancet Glob Health, 11, e296 - e300
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Hamaluba M. et al, (2023), Wellcome open research, 8
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Hamaluba M. et al, (2023), Wellcome Open Res, 8